Glaucoma neuroprotection: What is it? Why is it needed?

被引：54
|
作者：
Weinreb, Robert N. [1 ]
机构：
[1] Univ Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA
来源：
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE | 2007年 / 42卷 / 03期
关键词：
glaucoma; neuroprotection; glaucoma treatment; glaucoma neuroprotection;
D O I：
10.3129/i07-045
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The glaucomas are a group of ocular diseases characterized by progressive optic nerve damage and visual loss. Although there is good laboratory evidence for glaucoma neuroprotection by several drugs, the evidence from randomized clinical trials is lacking.
引用
收藏
页码：396 / 398
页数：3
相关论文
共 50 条
  • [21] SCHOOL PHYSICIANS - WHAT DO THEY DO AND WHY ARE THEY NEEDED
    GOLDBERG, ES
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 1982, 3 (03): : 179 - 181
  • [22] TRP channels: what are they and why are they important as a new target for neuroprotection
    Minke, B.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 45 (SUPPL 1) : S83 - S83
  • [23] Neuroprotection in glaucoma - Introduction
    Brancato, R
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 1999, 9 (01) : S1 - S1
  • [24] Pharmacological Neuroprotection for Glaucoma
    Gábor Holló
    Drugs, 2007, 67 : 2291 - 2291
  • [25] Neuroprotection in glaucoma - Overview
    不详
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 1999, 9 (01) : S3 - S3
  • [26] Pharmacological neuroprotection for glaucoma
    Chidlow, Glyn
    Wood, John P. M.
    Casson, Robert J.
    DRUGS, 2007, 67 (05) : 725 - 759
  • [27] Autoimmunity and neuroprotection in glaucoma
    Grus, F.
    ACTA OPHTHALMOLOGICA, 2014, 92
  • [28] Pharmacological Neuroprotection for Glaucoma
    Glyn Chidlow
    John P. M. Wood
    Robert J. Casson
    Drugs, 2007, 67 : 725 - 759
  • [29] Pharmacological neuroprotection for glaucoma
    Hollo, Gabor
    DRUGS, 2007, 67 (15) : 2291 - 2291
  • [30] Targets of Neuroprotection in Glaucoma
    He, Shaoqing
    Stankowska, Dorota L.
    Ellis, Dorette Z.
    Krishnamoorthy, Raghu R.
    Yorio, Thomas
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (1-2) : 85 - 106
12345